FY2025 Earnings Estimate for uniQure Issued By William Blair

uniQure N.V. (NASDAQ:QURE) – Equities researchers at William Blair cut their FY2025 EPS estimates for shares of uniQure in a report released on Monday, November 10th. William Blair analyst S. Corwin now forecasts that the biotechnology company will post earnings per share of ($3.91) for the year, down from their previous estimate of ($2.74). William Blair has a “Market Perform” rating on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. William Blair also issued estimates for uniQure’s Q4 2025 earnings at ($1.02) EPS, Q1 2026 earnings at ($1.03) EPS, Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($1.13) EPS, Q4 2026 earnings at ($1.18) EPS and FY2026 earnings at ($4.40) EPS.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.

Several other research firms have also commented on QURE. Chardan Capital reissued a “buy” rating and issued a $53.00 price objective on shares of uniQure in a research note on Tuesday. Stifel Nicolaus raised their price target on shares of uniQure from $30.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, August 2nd. HC Wainwright decreased their target price on uniQure from $110.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, November 4th. Finally, Benchmark restated a “buy” rating on shares of uniQure in a report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $64.42.

uniQure Stock Performance

Shares of uniQure stock opened at $30.12 on Wednesday. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -7.68 and a beta of 0.59. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. The business has a 50-day moving average of $42.80 and a 200 day moving average of $24.54. uniQure has a 12 month low of $5.50 and a 12 month high of $71.50.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 226,316 shares of the firm’s stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the sale, the chief executive officer owned 651,454 shares of the company’s stock, valued at approximately $27,009,282.84. This trade represents a 25.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Christian Klemt sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $55.00, for a total value of $825,000.00. Following the completion of the transaction, the chief financial officer directly owned 217,730 shares of the company’s stock, valued at $11,975,150. This trade represents a 6.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 314,560 shares of company stock worth $12,362,568. Insiders own 4.79% of the company’s stock.

Institutional Investors Weigh In On uniQure

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Private Trust Co. NA acquired a new position in uniQure in the third quarter valued at $28,000. Jones Financial Companies Lllp lifted its holdings in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of uniQure by 358.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 5,538 shares during the period. KLP Kapitalforvaltning AS purchased a new position in uniQure during the 2nd quarter worth approximately $117,000. Finally, Teacher Retirement System of Texas purchased a new position in uniQure during the 2nd quarter worth approximately $151,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.